Biomedical Engineering Reference
In-Depth Information
in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;
158:1664-1668.
86. Takanashi S, Hasegawa Y, Kanehira Y, Yamamoto K, Fujimoto K, Satoh K,
et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD
and in smokers. Eur Respir J 1999; 14:309-314.
87. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al.
Recombinant human interleukin 10 in the treatment of patients with mild
to moderately active Crohn's disease. Gastroenterology 2000; 119:1473-1482.
88. Culpitt SV, Rogers DF, Fenwick PS, Shah P, de Matos C, Russell RE, et al.
Inhibition by red wine extract, resveratrol, of cytokine release by alveolar
macrophages in COPD. Thorax 2003; 58:942-946.
89. Vestbo J. Epidemiological studies in mucus hypersecretion. Novartis Found
Symp 2002; 248:3-12.
90. Barnes PJ. Current and future therapies for airway mucus hypersecretion.
Novartis Found Symp 2002; 248:237-249.
91. Nadel JA, Burgel PR. The role of epidermal growth factor in mucus produc-
tion. Curr Opin Pharmacol 2001; 1:254-258.
92. Zhou Y, Shapiro M, Dong Q, Louahed J, Weiss C, Wan S, et al. A calcium-
activated chloride channel blocker inhibits goblet cell metaplasia and mucus
overproduction. Novartis Found Symp 2002; 248:150-165.
93. Rogers DF. Pharmacological regulation of the neuronal control of airway
mucus secretion. Curr Opin Pharmacol 2002; 2:249-255.
94. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, et al.
Increased expression of transforming growth factor-pi in small airway epithe-
lium from tobacco smokers and patients with chronic obstructive pulmonary
disease (COPD). Am J Respir Crit Care Med 2001; 163:1476-1483.
95. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent trans-
forming growth factor-
a
(TGF-
b
)-binding protein-1 by osteoclasts. A cellular
mechanism for release of TGF-b from bone matrix. J Biol Chem 2002;
277:21352-21360.
96. Yakymovych I, Engstrom U, Grimsby S, Heldin CH, Souchelnytskyi S. Inhi-
bition of transforming growth factor-b signaling by low molecular weight
compounds interfering with ATP- or substrate-binding sites of the TGF
b
type
I receptor kinase. Biochemistry 2002; 41:11000-11007.
97. DaCosta BS, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhi-
bitor of transforming growth factor-b type I receptors ALK4, ALK5, and
ALK7. Mol Pharmacol 2004; 65:744-752.
98. Miotto D, Hollenberg MD, Bunnett NW, Papi A, Braccioni F. Boschetto P,
et al. Expression of protease activated receptor-2 (PAR-2) in central airways
of smokers and non-smokers. Thorax 2002; 57:146-151.
99. Vliagoftis H, Schwingshackl A, Milne CD, Duszyk M, Hollenberg MD,
Wallace JL, et al. Proteinase-activated receptor-2-mediated matrix metallo-
proteinase-9 release from airway epithelial cells. J Allergy Clin Immunol
2000; 106:537-545.
100. Frungieri MB, Weidinger S, Meineke V, Kohn FM, Mayerhofer A. Prolifera-
tive action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins,
